Institute for Translational Epidemiology at the Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
EpidStrategies, Rockville, Maryland, United States of America.
PLoS One. 2022 Aug 30;17(8):e0271339. doi: 10.1371/journal.pone.0271339. eCollection 2022.
The role of interferon gamma (IFN-γ) expression in long-term survival has not been studied in patients with urinary bladder cancer (UBC). IFN-γ expression was characterized among various UBC patient cohorts to assess if IFN-γ status is associated with overall survival (OS).
A tumor-based IFN-γ gene signature was evaluated among adult UBC patients newly diagnosed between 2004 and 2017 from two hospital systems in New York. Patient cohorts included metastatic (stage IV or progressing to stage IV [MBC]), muscle-invasive (stages T2a to T4a [MIBC]), and non-muscle-invasive (carcinoma in situ or stages 0a, 0is, and I [NMIBC]) disease. Descriptive analyses were conducted comparing IFN-γ signature in the highest tertile to those in the lowest two tertiles.
234 patients with bladder cancer were evaluated (56 MBC, 38 MIBC, and 140 NMIBC). Median OS was only reached in the MIBC cohort for those with an IFN-γ signature in the lowest two tertiles (15.03 months [95% CI, 8.50-50.60]). Those with an IFN-γ signature in the highest tertile had a decreased risk of mortality in all cohorts indicating better survival, but this was statistically significant in only the MIBC cohort (adjusted HR = 0.09 [95% CI, 0.01-0.73]).
IFN-γ signature status was associated with a decreased mortality risk in all cohorts, particularly MIBC, indicating that it may be a prognostic marker of survival in patients with UBC.
干扰素 γ（IFN-γ）表达在膀胱癌（UBC）患者的长期生存中的作用尚未得到研究。在各种 UBC 患者队列中对 IFN-γ表达进行了特征描述，以评估 IFN-γ状态是否与总生存（OS）相关。
在纽约的两个医院系统中，对 2004 年至 2017 年间新诊断为 UBC 的成年患者进行了基于肿瘤的 IFN-γ基因特征评估。患者队列包括转移性（IV 期或进展为 IV 期[MBC]）、肌层浸润性（T2a 至 T4a 期[MIBC]）和非肌层浸润性（原位癌或 0a、0is 和 I 期[NMIBC]）疾病。进行描述性分析，比较最高三分位组和最低两个三分位组的 IFN-γ特征。
评估了 234 例膀胱癌患者（56 例 MBC、38 例 MIBC 和 140 例 NMIBC）。只有在 IFN-γ特征处于最低两个三分位组的 MIBC 患者中才达到中位 OS（15.03 个月[95%CI，8.50-50.60]）。在所有队列中，IFN-γ特征处于最高三分位组的患者死亡风险降低，表明生存情况更好，但仅在 MIBC 队列中具有统计学意义（调整后的 HR=0.09[95%CI，0.01-0.73]）。
IFN-γ特征状态与所有队列中的死亡率降低风险相关，特别是在 MIBC 队列中，表明它可能是 UBC 患者生存的预后标志物。
